AstraZeneca, Flying Solo, Sees Momentum Take Off In Diabetes
The company launched three diabetes drugs in 2014, just after breaking off a joint venture with Bristol-Myers and taking over full control of the business. U.S. President Paul Hudson talked about the evolution of AstraZeneca’s diabetes business – and where it stands today – in a recent interview.
You may also be interested in...
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.
Lilly’s Glyxambi Is First SGLT2/DPP-4 Combo Product For Diabetes
Glyxambi is the latest in a series of new diabetes drugs for Eli Lilly, following on the heels of Jardiance and Trulicity. The company highlighted new drugs and its pipeline during its year-end financial call.
With Oncology Drugs On The Way, AstraZeneca Sets The Stage For New Launches
U.S. President Paul Hudson says AstraZeneca is building specialty commercial team ahead of new oncology launches; MedImmune seals new deals in its quest for winning combinations in immuno-oncology.